NTII Neurobiological Technologies (MM)

EMERYVILLE, Calif., Dec. 21 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI (R)) (NASDAQ:NTII) today announced the retirement of Dr. Ronald E. Cape as Director, effective December 31, 2007. Paul Freiman, president and chief executive officer stated, "We have accepted Dr. Cape's resignation upon the occasion of his 75th birthday. Dr. Cape is a legend in the biotechnology industry and his service on our board has been outstanding. Prior to joining the board, Dr. Cape served as an advisor to the company and we are pleased that he has agreed to continue to be available to advise us." About Neurobiological Technologies, Inc. NTI is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stage clinical trials for central nervous system conditions. The Company is currently developing Viprinex(TM) (ancrod), a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke. DATASOURCE: Neurobiological Technologies, Inc. CONTACT: Paul E. Freiman, President & CEO of Neurobiological Technologies, Inc., +1-510-595-6000 Web site: http://www.ntii.com/

Copyright